1 / 46

S. Kol, May 2006

Prevention of OHSS. S. Kol, May 2006. OHSS – scope of the problem. Severe form: 0.2-1% of stimulation cycles. Mortality: 1:45,00 to 1:50,000 per infertile women receiving gonadotropins. WHO 2001. OHSS: incidence, recent data.

shika
Télécharger la présentation

S. Kol, May 2006

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prevention of OHSS S. Kol, May 2006

  2. OHSS – scope of the problem • Severe form: 0.2-1% of stimulation cycles. • Mortality: 1:45,00 to 1:50,000 per infertile women receiving gonadotropins. WHO 2001

  3. OHSS: incidence, recent data • Two large trials, 1458 patients, agonist-based protocol, comparing Menopur and Gonal F (Arce and Sorensen, ASRM 2005) • Patients at high risk for OHSS - “drop-outs”. • Moderate – severe OHSS: 2%

  4. F&S January 2006 Objective: to determine OHSS incidence in 2,524 antagonist-based cycles (1801 patients). Results: fifty three patients (2%) were hospitalized because of OHSS. Conclusions: clinically significant OHSS is a limitation even in antagonist cycles. “There is more than ever an urgent need for alternative final oocyte maturation – triggering medication”

  5. Morbidity • An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion. • Case report: delirium associated with ovarian hyperstimulation syndrome. • Cortical vein thrombosis misinterpreted as intracranial haemorrhage in severe ovarian hyperstimulation syndrome: case report. • Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. • A severe case of ovarian hyperstimulation syndrome: 65 liters of ascites aspirated in an on-going IVF-ET twin pregnancy. • Central retinal artery occlusion associated with severe ovarian hyperstimulation syndrome. • A case of forearm amputation after ovarian stimulation for in vitro fertilization-embryo transfer. • Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA. • Internal jugular vein thrombosis: a late complication of ovarian hyperstimulation syndrome despite mini-dose heparin prophylaxis. and more and more…

  6. Past predictions of the future “We don’t like their sound, and guitar music is on the way out” Decca Recordings Co. rejecting the Beatles, 1962. “Stocks have reached what looks like a permanently high plateau”. Irving Fisher, Professor of Economics. Yale University, 1929. “$100 million is way too much to pay for Microsoft” IBM 1982. “Who the hell wants to hear actors talks?” H.M. Warner, Warner Brothers, 1927. “Severe OHSS will remain a complication of IVF cycles despite all attempts of prevention.” R.G. Forman, Human Reproduction 14:2687, 1999. “…absolute prevention will not be possible” García-Velasco et al F&S, March 2006.

  7. Accepted preventive strategies • Canceling the cycle • Coasting • Albumin IV • Cryopreservation • Recombinant LH • Low hCG dose

  8. Coasting • Most popular choice. • Open questions: for whom? how many days? Safe value to give hCG? Magnitude of E2 drop? • Cochrane database: D'Angelo A, Amso N. Coasting for preventing ovarian hyperstimulation syndrome. The Cochrane Database 2002“There is a lack of randomised controlled trials…there is insufficient evidence to determine if coasting is an effective strategy for preventing OHSS.”

  9. IV albumin • Conflicting results. • Cochrane database: Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. The Cochrane Database of Systematic Reviews 2002: “Clear benefit from administration of intra-venous albumin at the time of oocyte retrieval in prevention of severe OHSS in high-risk cases”. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Bellver at al 2003 The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Ben-Chetrit et al 2001 Personal communication with Professor Aboulghar: review amendment: albumin is ineffective.

  10. Cryopreservation • OHSS can be severe until menses. • Cochrane database:D'Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. The Cochrane Database of Systematic Reviews 2002, “insufficient evidence to support routine cryopreservation and insufficient evidence for the relative merits of intra-venous albumin versus cryopreservation“

  11. Recombinant LH • Not available as trigger. • No data on OHSS prevention. • In theory, will not prevent late, pregnancy-associated, OHSS.

  12. Low hCG dose • Questionable, unreliable. • “Reducing the dose of hCG does not eliminate the risk of OHSS in a high risk group” Schmidt el al, Fertility Sterility October 2004

  13. “Severe OHSS will remain a complication of IVF cycles despite all attempts of prevention.” R.G. Forman, Human Reproduction 14:2687, 1999. Total OHSS prevention can only be achieved by ovulation triggering with a GnRH agonist.

  14. The GnRHa-induced LH/FSH surge • LH and FSH levels rise 4 and 12 hours post trigger, respectively. • LH surge lasts for 24 hours. • Surge amplitude comparable to physiology. • A single agonist dose reliably triggers ovulation. Itskovitz et al 1991

  15. Luteal phase • Normal early follicular-luteal shift in ovarian steroidogenesis. • Short luteal phase: early luteolysis.

  16. Case-control study(Lewit et al Hum Reprod 11:1399, 1996) • 16 patients who developed severe OHSS when hCG was given as trigger (group A). • Each patient underwent at least 1 cycle during which GnRH agonist was given as trigger (triptorelin 0.2 mg, group B). • In group B – no OHSS!!!

  17. Stimulation variables Lewit et al

  18. Oocyte quality Lewit et al

  19. Limitations • Prospective study – ethical dilemma? • Not applicable in agonist-based cycles: unresponsive pituitary. Use antagonists???

  20. Efficacy GnRHa vs hCG for triggering of final oocyte maturation Fauser et al, JCEM Feb. 2002, 87:709 • Objective: Can agonists trigger ovulation as effective as hCG? • Randomized prospective multi-center study. • Antagonist-based cycles, normal responders. • Outcome measures: number of metaphase II oocytes

  21. Protocol Fauser et al, 2002

  22. Clinical outcome (mean±SD) Fauser et al, 2002

  23. Serum concentrations of LH (hCG), FSH, E2 and P Fauser et al, 2002

  24. Can this approach prevent OHSS?

  25. Human Reproduction, September 2000 • Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication • J. Itskovitz-Eldor et al

  26. Treatment scheme for high responders Day 2-3 menses Day 6 rFSH High responder - triptorelin 0.2mg Rec FSH OPU ET ganirelix Progesterone

  27. Stimulation characteristics of 8 women with increased risk for developing OHSS and who received 0.2 mg triptorelin for triggering ovulation Sub. rFSH (IU) Foll11mm E2 pg/ml Oocytes %MII 7 1350 22 2980 29 100 33 1500 21 3660 14 100 39 1950 24 3350 30 90 108a 1875 22 6410 1 100 109 1275 28 7670 52 54 112 1575 34 4050 30 93 126 2175 22 3690 15 67 158 1575 28 3020 16 56 a Empty follicle syndrome No OHSS !!!

  28. Results • Mean no. of follicles>11mm=25.1±4.5 • Median E2(pg/ml)=3675 (range 2980–7670) • Mean number of oocytes=23.4 (±15.4), 83% MII • Mean number of embryos=15.4±6.6 • 7 ETs from fresh embryos: 1 pregnancy • 17 ETs from frozen-thawed embryos: 4 pregnancies Itskovitz et al, 2000

  29. Median values of serum LH and E2 after injection of triptorelin 0.2mg Itskovitz et al, 2000

  30. Lower levels of inhibin A and pro-alpha C during the luteal phase after triggering oocyte maturation with GnRH agonist versus hCG Mechanism Nevo et al, Fertil Steril 79:1123, 2003 What is the mechanism of OHSS prevention?

  31. Clinical characteristics Nevo et al, 2003

  32. Luteal phase Natural cycle day 7-9= 75 pg/ml vs. 18 Natural cycle day 7-9= 750 pg/ml vs. 184 Nevo et al, 2003

  33. Evidence-based medicine • We need a RCT in the context of OHSS prevention. • Study group: agonist trigger, control group: hCG trigger. • The ethical problem of exposing high-responders to the risk of OHSS.

  34. Prevention of OHSS with the use of GnRH agonist to trigger final oocyte maturation after cotreatment with GnRH antagonist in patients with PCOS or previous high response undergoing IVF treatment - a prospective randomized clinical trial. L. Engmann, A. DiLuigi, D. Schmidt, J. Nulsen, D. Maier, C. Benadiva University of Connecticut ASRM October, 2005

  35. Study Design • < 40years, FSH < 10 with • PCOS or PCO Morphology • Or Previous High Response Randomization N=13 N=12 Dual suppression OCP’s & luprolide HCG trigger OCP’s + Ganirelix luprolide trigger LUTEAL SUPPORT: E2 patches 0.1 mg X 3, qod P4 in oil, 50 mg/day; MONITOR E2+P4 LEVELS!

  36. Engmann et al

  37. Incidence of OHSS (April 2006 update) N=27 P<0.001 N=25 % Engmann et al

  38. Outcome(April 2006 update) 65.4% 60% 60.7% 56% 51.9% 48.1% 37.2% % 31.7% Engmann et al

  39. *p<0.05 Babayof et al HR May 2006

  40. Agonist trigger in normal responders? Since there are no ethical problems, we can trigger with agonist, although there is no reason to look for a substitute to hCG: • GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. HR Humaidan et al, May 2005. • A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. HR Kolibianakis et al, October 2005. • GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. HR Update Griesinger et al, March 2006.

  41. The importance of luteal support?

  42. IVF Haifa: retrospective data analysis • 107 high responders, 2004-5 • E2 max (pmol/l)=17,268±6305 • No. oocytes: 30±7.3 • No. embryos: 15.2±6.5

  43. Endometrial effect of high E2 levels • High serum estradiol concentrations on the day of HCG injection are detrimental to uterine receptivity without affecting embryo quality. Simon et al, HR, 1995. • Implantation rate was significantly higher in normal (18.5%) as compared with high (0%) responders. Pellicer et al FS, 1996

  44. Summary • Agonist trigger is an effective alternative to hCG. Its use is associated with dramatic and irreversible luteolysis. • This remarkable phenomenon can be utilized to completely and reliably prevent OHSS, even in extreme ovarian response. • Aggressive luteal support is necessary. • Agonist trigger in high responders is associated with low fresh cycle pregnancy rate, probably due to the extremely high E2 levels. • Thaw cycles with embryos obtained after agonist trigger yield good pregnancy rate. • Agonist trigger offers no advantage in normal responders. • Agonist trigger is the perfect patient-tailored safe-gate if a patient hyper-responds.

  45. skol@rambam.health.gov.il Thank you

More Related